W. L. Gore & Associates, Inc., a global materials science company, is advancing the field of membrane chromatography through the development of new affinity membrane devices in collaboration with leading customized ligand partners. These alliances will integrate partner-developed ligand technologies with Gore’s proven high-productivity membrane platform to deliver innovative purification solutions for a broader range of biotherapeutic modalities.
The new products are designed to enhance purification productivity, scalability, cost-effectiveness, and reduce risk across applications such as cell and gene therapies, more specialized antibody-based therapies, and more. Through these collaborations, Gore and in some cases Gore’s ligand partners will market and distribute the affinity membrane devices under their respective brands, ensuring broad accessibility and customer support worldwide.
“At Gore, we are committed to helping our customers accelerate the discovery, development, and delivery of vital therapies,” said Russ Hornung, Business Development Manager at Gore. “By working with customized ligand partners, we’re combining complementary expertise to bring advanced membrane-based affinity solutions to market and expand our role in downstream bioprocessing beyond only Protein A technologies.”
Gore’s affinity membranes offer a scalable and intensified purification platform that delivers reliable performance from R&D, process development, clinical bioprocessing, and through to GMP-scale manufacturing. With high binding capacity at fast residence times, low pressure drop, and sharp and consistent elution performance, Gore membranes are engineered to meet the evolving needs of modern bioprocessing.
“Our high-productivity membranes are designed to deliver consistent high speed, capacity, and reliability at scale,” added Jeff Cassel, Chromatography Director for Gore PharmBIO Products. “Partnering with ligand technology innovators allows us to broaden our membrane chromatography portfolio and helps customers achieve higher productivity, flexibility, and cost effectiveness across multiple purification challenges and modalities.”
